TBPH

Business Context and Reporting Period

Company: Theravance Biopharma, Inc. (TBPH)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: A biopharmaceutical company focused on respiratory and neurological therapeutics. Its primary commercial asset is YUPELRI (revefenacin) for COPD, co-promoted with Viatris Inc. Its lead development candidate is ampreloxetine for neurogenic orthostatic hypotension in Multiple System Atrophy (MSA). The company also holds a long-term economic interest in GSK's TRELEGY via Royalty Pharma Investments.

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The company reported no long-term debt as of December 31, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 12% to $64.4 million, driven by a 13% increase in revenue from the Viatris collaboration agreement. This reflects an 8% increase in total YUPELRI net sales to $238.6 million, with hospital volumes growing 41%.
• Expense Reductions: Research and Development (R&D) expenses decreased 7% to $37.6 million, primarily due to reduced share-based compensation and facility costs following 2023 strategic actions. Selling, General, and Administrative (SG&A) expenses remained relatively flat at $69.2 million.
• Impairment Charges: The company recognized a non-cash impairment charge of $4.5 million related to operating lease assets and leasehold improvements in South San Francisco, compared to none in 2023.
• Tax Expense: Provision for income tax expense increased to $11.8 million (from $5.9 million), primarily attributed to uncertain tax positions and interest on historical positions.
• Cash Flow Improvement: Net cash used in operating activities improved significantly to $11.5 million from $27.0 million in the prior year.

Guidance, Outlook, and Strategic Developments

• TRELEGY Milestone: In February 2025, the company received a $50.0 million milestone payment from Royalty Pharma Investments, triggered by TRELEGY achieving $3.46 billion in global net sales for 2024. An additional $150.0 million in potential milestones remains available through 2026.
• Ampreloxetine Development: Enrollment in the Phase 3 CYPRESS study for ampreloxetine is on track for completion in mid-2025, with data expected approximately six months later.
• Strategic Review: In November 2024, the Board formed a Strategic Review Committee to assess all strategic alternatives, including potential transactions related to YUPELRI, ampreloxetine, and TRELEGY, to unlock shareholder value. No timetable or assurance of a transaction was provided.
• Liquidity: Management expects current cash and marketable securities ($88.4 million) to be sufficient to fund operations for at least the next twelve months.
• Patent Litigation: As of February 28, 2025, the company settled litigation with five generic companies regarding YUPELRI, granting licenses for generic launch on or after April 23, 2039. Litigation against three remaining generic companies remains pending.

Investor Verification Checklist

• Strategic Review Outcome: Monitor for updates on the Strategic Review Committee's assessment of potential transactions or asset sales.
• Ampreloxetine Phase 3 Data: Verify the timeline and results of the CYPRESS study readout expected in late 2025/early 2026.
• TRELEGY Milestone Triggers: Track GSK's TRELEGY sales performance to determine eligibility for the remaining $150 million in milestone payments in 2025 and 2026.
• Generic Competition: Follow the status of pending patent litigation against the three remaining generic companies for YUPELRI.
• Cash Burn Rate: Assess the sustainability of the $88.4 million cash position given the ongoing costs of the ampreloxetine trial and commercial operations.